The 57th American Society of Hematology (ASH) Annual Meeting will be held this year from Dec. 5–Dec. 8. This will be my first up-close experience at ASH. Needless to say, I feel there is much more to learn as I prepare.
I am grateful to the International Myeloma Foundation (IMF) for inviting me to ASH, and I look forward to sharing exciting research updates with myeloma patients and their caregivers.
Stem Cell Transplantation (SCT) choices are one area I would like to follow while at ASH. It continues to be a broad topic—but one that remains an integral part of treatment choices.
The other topic I would like to learn more about has to do with relapse therapy studies and how they can apply to myeloma patients. The options today have really been impacted with the newer targeted therapies.
These are exciting times!